Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of RB-ADSC in Mild-Moderate Alzheimer's Disease
NCT05667649Phase 1Completed
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 1, open-label trial of astrostem in Alzheimer's disease (AD) (3 arms). Primary endpoint: Safety of RB-ADSC treatment at 28 weeks. Started Aug 2023; status: completed.
02
Drugs
astrostem
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05667649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667649.